Medical Products & Consumables Procurement Optimisation · Technical White Paper
Medical Products & Consumables Procurement — Technical White Paper
Invoice reconstruction, product due diligence, supplier negotiation, clinical acceptance governance and the result-state discipline that keeps an opportunity honest.
Publication boundary
Modelled and provisional results only. Neither the initial R992,546.18 opportunity nor the later R1,788,234.30 provisional position is presented as a realised annual saving — the source evidence does not support that classification for the whole amount.
Client, supplier and product-brand identities are withheld, as are unit rates. The engagement’s limitations are stated rather than smoothed over.
Executive overview
The commercial question could not be answered on its own
Medical-product purchasing was reconstructed from supplier invoices across twelve months and separated into three sectors. The analysis moved below supplier totals to individual products, quantities, price ranges and purchasing patterns.
What makes this engagement distinctive is not the size of the opportunity but the gate placed in front of it. In healthcare procurement, commercial optimisation cannot be separated from clinical suitability — so commercial and product-validation work ran as parallel tracks, and the client’s clinical specialists retained the acceptance decision at every point.
6. Product-level due diligence
Comparing products, not brands
Scroll table sideways →
| Comparison field | Why the field matters |
|---|---|
| Intended use | Establishes whether the comparison is functionally relevant at all |
| Available sizes | A price advantage is unusable if the patient’s required size is absent |
| System format | One-piece and two-piece architecture affects accessories and the user’s daily routine |
| Wear and fit characteristics | Product behaviour can determine leakage risk and user acceptance |
| Price range | Varies by size, so a single headline price is not a comparison |
| Related accessories | Base plates and ancillary requirements can move cost outside the compared item |
The control was never the brand name. It was whether the alternative could meet the patient’s physical and clinical requirements, and whether the product family contained an appropriate equivalent for the specific item being replaced.
11. Clinical acceptance governance
An iterative process, not a single sign-off
Scroll table sideways →
| Stage | Recorded decision | Financial effect |
|---|---|---|
| 20 February 2024 | Primary and ancillary alternatives presented for specialist input; patient choice and prescription factors raised | Initial opportunity remains provisional pending product feedback |
| 4 March 2024 | Primary stoma products to remain unchanged; ancillary described as open to alternatives | Primary substitution scope narrows materially |
| 18 March 2024 | Further repricing, supplier negotiation, institutional-supplier meetings and anomaly work agreed | Opportunity shifts toward repricing plus selective alternatives |
| 3 April 2024 | Alternative products reported accepted after due diligence; further alternatives requested | Candidates move toward implementation, subject to exact-product control |
| 5 April 2024 | At least one previously accepted alternative later rejected or reconsidered | Associated benefit can no longer be treated as implementation-ready without resolution |
Clinical review did not make optimisation impossible. It changed the set of savings that could responsibly remain in the implementable model. A rejected alternative is a control event that improves the reliability of the final result.
12. Product-identity control
A rejection is only useful if it names the right product
A later dispute exposed a subtle governance failure: the rejection reason appeared to describe a different product from the one that had been proposed and approved. The documentation distinguished a convex barrier-ring product from a different mouldable-ring product discussed in clinical feedback.
This is a classic master-data problem. Similar product names, several rings and seals in the same functional family, and multiple alternatives discussed in one meeting can produce a mismatch between the item being evaluated and the item recorded in the workbook. Once that happens, a saving can be removed for the wrong reason — or retained despite a genuine rejection.
The rule that follows: every approval or rejection must link to an exact product identifier, supplier, description, size and configuration, decision date and named approver. Product-family language should never be the sole key in a clinically sensitive savings model.
12.1 Minimum approval record
Ten fields that make a clinical decision auditable
Scroll table sideways →
| Field | Required entry | Reason |
|---|---|---|
| Current product | Exact code and description | Defines what is being replaced |
| Alternative product | Exact code and description | Prevents confusion with another product in the same family |
| Supplier | Commercial source | Confirms the route to which pricing applies |
| Pack / size / configuration | Comparable unit basis | Avoids approval of a different pack or clinical size |
| Clinical reviewer | Named authorised specialist | Creates decision accountability |
| Decision | Accepted / rejected / conditional / trial | Avoids ambiguous meeting language |
| Reason | Short technical rationale | Allows later audit and model correction |
| Effective date | Date the decision applies | Supports version control |
| Commercial price version | Quote or price-list date | Prevents mixing an accepted product with an expired price |
| Model link | Workbook row or decision ID | Ensures the calculation uses the same product record |
13. Invoice anomalies
Seven steps from variance to recovery
Identify the price variance
Use invoice-level data to isolate dates, quantities, invoice numbers and unit rates.
Establish the agreed comparator
Locate the applicable quotation, price list, contract schedule or purchase order.
Test period validity
Confirm the comparator applied on the transaction date and had not been superseded.
Reconcile quantities and credits
Check whether rebates, credit notes, backdated adjustments or free stock altered the effective price.
Obtain supplier response
A variance is a question until the supplier confirms or disputes it.
Reconcile any counter-claim
Do not net an asserted supplier undercharge against a client overcharge without transaction-level evidence.
Recognise only the resolved amount
Recovery becomes a result when a credit, refund, corrected invoice or agreed adjustment is evidenced.
11.1 Patient uptake
Assuming full conversion overstates the value
Specialists identified several reasons why uptake could differ from a purely commercial recommendation. Patients may be accustomed to an existing product. A doctor may have prescribed a particular one. Stoma shape and skin condition affect fit. Medical-aid exhaustion can create demand for lower-cost alternatives later in the benefit cycle.
Substitution may therefore need to be patient-selective rather than portfolio-wide — which changes how savings should be measured. Where uptake is uncertain, the correct approach is to calculate scenario ranges, or to measure realised conversion from transaction data, rather than assume full migration.
19. Limitations
What remained unproven, stated plainly
- Early data completeness. The first clinical review rested on an invoice set described as roughly 80–85% complete.
- Changing product acceptance. Status changed during the engagement; any model tied to an earlier state must be recalculated.
- Patient uptake uncertainty. Even an accepted alternative may not achieve full portfolio conversion.
- Supplier terms still developing. New pricing could carry conditions such as contractual commitments and further qualification.
- Accounting cross-reference in progress. The later provisional model was still being reconciled to the accounting system.
- Supply transition. A distributor change created uncertainty over product continuity and future prices.
- Anomaly counter-position. A supplier asserted an undercharge requiring further reconciliation.
- Mandate interruption. Some planned supplier and medical work was halted, limiting completion of implementation steps.